NANOSYNEX LTD

Their core work

Nanosynex is an Israeli medtech SME developing ultra-fast antimicrobial susceptibility tests (AST) that tell doctors within hours — not days — which antibiotic will actually kill a patient's specific infection. Their diagnostic technology directly tackles antimicrobial resistance, one of the WHO's top global health threats, by replacing slow culture-based lab work with rapid, personalized results at the point of care. The company operates at the intersection of nanotechnology, microbiology, and clinical diagnostics, targeting hospitals and clinical labs that need faster sepsis and bloodstream infection workflows.

What they specialise in

How they've shifted over time

Nanosynex has not changed direction — they have deepened it. The 2018 SME-1 feasibility grant (EUR 50K) validated the business case for their ultra-fast AST; the 2020-2025 SME-2 grant (EUR 2.56M, a 50x jump) funds clinical scale-up of the same technology. This is a textbook focused-SME trajectory: one product, one clinical problem, two stages of EU support pushing it from concept toward market.

Heading toward market launch and clinical adoption of their AST product — a partner here is buying into a maturing diagnostic, not an early-stage research idea.

How they like to work

Nanosynex has used the SME Instrument as a single-beneficiary funding route — they coordinate both projects but the H2020 data shows no consortium partners, which is normal for the SME-1/SME-2 scheme. This means they have run focused, internally-driven product development rather than large research consortia. Partners considering them should expect a lean, commercial-minded counterpart rather than an academic-style collaborator.

No formal H2020 consortium partners are recorded, since both grants are single-beneficiary SME Instrument awards. Their visible EU footprint is therefore Israel-only on paper, though the SME-2 phase typically involves clinical and commercial partners outside the funding record.

What sets them apart

They are a focused, single-product Israeli SME that has cleared both stages of the EU SME Instrument gauntlet — a strong external signal that their AST technology was judged commercially credible by independent EU evaluators. Unlike academic groups working on AMR, Nanosynex is building a clinical product on a defined timeline. For a hospital network, distributor, or diagnostics company, the value is access to a near-market rapid AST tool rather than an early research collaboration.

Highlights from their portfolio

• Nanosynex (SME-2, 2020-2025)
  EUR 2.56M single-beneficiary grant to scale their ultra-fast AST toward clinical use — their flagship project and one of the larger SME-2 awards in diagnostics.
• Nanosynex (SME-1, 2018)
  Earlier EUR 50K feasibility grant that successfully bridged into the much larger SME-2 award — evidence the technology passed EU commercial validation twice.